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Abstract
Background: Galectin-9 (Gal-9) is a mammalian lectin secreted by endothelial cells that is highly expressed in
rheumatoid arthritis synovial tissues and synovial fluid. Roles have been proposed for galectins in the regulation of
inflammation and angiogenesis. Therefore, we examined the contribution of Gal-9 to angiogenesis and inflammation
in arthritis.
Methods: To determine the role of Gal-9 in angiogenesis, we performed human dermal microvascular endothelial cell
(HMVEC) chemotaxis, Matrigel tube formation, and mouse Matrigel plug angiogenesis assays. We also examined the
role of signaling molecules in Gal-9-induced angiogenesis by using signaling inhibitors and small interfering RNA (siRNA).
We performed monocyte (MN) migration assays in a modified Boyden chamber and assessed the arthritogenicity of Gal-9
by injecting Gal-9 into mouse knees.
Results: Gal-9 significantly increased HMVEC migration, which was decreased by inhibitors of extracellular signal-regulating
kinases 1/2 (Erk1/2), p38, Janus kinase (Jnk), and phosphatidylinositol 3-kinase. Gal-9 HMVEC-induced tube formation was
reduced by Erk1/2, p38, and Jnk inhibitors, and this was confirmed by siRNA knockdown. In mouse Matrigel plug assays,
plugs containing Gal-9 induced significantly higher angiogenesis, which was attenuated by a Jnk inhibitor. Gal-9 also
induced MN migration, and there was a marked increase in MN ingress when C57BL/6 mouse knees were injected
with Gal-9 compared with the control, pointing to a proinflammatory role for Gal-9.
Conclusions: Gal-9 mediates angiogenesis, increases MN migration in vitro, and induces acute inflammatory arthritis in
mice, suggesting a novel role for Gal-9 in angiogenesis, joint inflammation, and possibly other inflammatory diseases.
Background
Galectins are a group of mammalian lectins with a high
affinity for β-galactosides that share a highly conserved
carbohydrate recognition domain (CRD) [1]. Three nat-
urally occurring splice variants of this gene exist, desig-
nated Gal-9 short, Gal-9 medium (Gal-9 M), and Gal-9
long, each corresponding to the relative length of the
linker peptide connecting the nonhomologous CRDs of
Gal-9 [2, 3]. Gal-9 M is a 323-amino acid splice variant
of the LGALS9 gene. Gal-9 causes apoptosis of CD4+ T-
helper 1 (TH1) cells at high concentrations [4, 5], but it
activates and expands TH1 cell populations at lower
concentrations [6]. Gal-9 is highly expressed in rheuma-
toid arthritis (RA) synovial fluid (SF) and synovial tissue
(ST) compared with normal or osteoarthritic ST [7],
suggesting a role for Gal-9 in RA.
Angiogenesis is a key aspect of both tumor growth
and RA in which the endothelium undergoes morpho-
logical changes resulting not only in expansion of the
vascular bed but also in increased leukocyte adhesion
and infiltration [8, 9]. Angiogenesis is mediated by the
mitogen-activated protein kinases (MAPKs), such as
extracellular signal-regulating kinases 1/2 (Erk1/2), Janus
kinase (Jnk), and p38 [10–14].
In this study, we found that Gal-9 M induces human
dermal microvascular endothelial cell (HMVEC) migra-
tion and tube formation on Matrigel, as well as in vivo
angiogenesis, via the Erk1/2, p38, and Jnk pathways.
Gal-9 M induces monocyte (MN) migration and acute
inflammation when injected into mouse knees,
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indicating the role of Gal-9 in angiogenesis and acute in-
flammation. Gal-9 also induces the phosphorylation of
Erk1/2, p38, and Jnk in HMVECs.
Methods
HMVEC chemotaxis assays
HMVECs (Lonza, Walkersville, MD, USA) were cultured
in endothelial basal media (Lonza). Recombinant human
Gal-9 M (Ecalectin; R&D Systems, Madison, WI, USA)
was used at various concentrations to perform HMVEC
chemotaxis [10–15]. To study the effects of signaling
molecules, we performed HMVEC migration assays with
Gal-9 in the presence or absence of the following inhibi-
tors: PD98059 (Erk1/2 inhibitor), LY294002 (phos-
phatidylinositol 3-kinase [PI3K] inhibitor), SB203580
(p38 MAPK inhibitor), and SP600125 (Jnk inhibitor).
These inhibitors were purchased from Calbiochem (San
Diego, CA, USA). Basic fibroblast growth factor (bFGF)
and PBS were used as positive and negative controls, re-
spectively. All the inhibitors were used at 10 μmol/L
concentration. To confirm the data obtained with chem-
ical signaling inhibitors, we transfected HMVECs with
small interfering RNA siRNA (Santa Cruz Biotechnol-
ogy, Dallas, TX, USA) of signaling molecules for 48 h
using Mirus transfection reagent (Mirus Bio, Madison,
WI, USA) and performed HMVEC chemotaxis using
Gal-9 M as a stimulus.
Matrigel in vitro HMVEC tube formation assays
To evaluate the effect of Gal-9 M on capillary morpho-
genesis, an HMVEC tube formation assay was per-
formed with different concentrations of Gal-9 M using
growth factor-reduced (GFR) Matrigel [11, 15]. To deter-
mine the effect of signaling molecules on Gal-9 M-
induced angiogenesis in vitro, HMVEC tube formation
assays were then performed with or without signaling
inhibitors. The data obtained with chemical signaling
inhibitors was confirmed using siRNAs against various
signaling molecules.
Immunoblotting and cell lysis
HMVECs were stimulated with Gal-9 M (27.9 nmol/L)
for various time points. To determine the role of signal-
ing molecules, HMVECs were incubated with chemical
signaling inhibitors for 1 h prior to stimulation with
Gal-9 M. To ensure equal loading, protein concentra-
tions of samples were determined using the Pierce
bicinchoninic acid protein assay kit (Thermo Fisher
Scientific, Rockford, IL, USA). Samples were then
analyzed by Western blotting using antibodies against
phosphorylated Erk1/2, p38, and Jnk (Cell Signaling
Technology, Danvers, MA, USA) [12, 16, 17]. Immuno-
blots were stripped and reprobed with β-actin and
antibodies to nonphosphorylated proteins to further
ensure equal loading.
Matrigel plug assay in vivo
Female C57BL/6 mice (aged 6–8 weeks; National
Cancer Institute, Bethesda, MD, USA) were injected
with GFR Matrigel (500 μl) containing Gal-9 M (L)
or PBS (control). Mice were/L) or PBS (control). Mice
were euthanized after day 7; the plugs were dissected;
and the amount of angiogenesis was determined by
hemoglobin measurement [10–13, 15]. Immunofluor-
escence was performed to evaluate the number of
blood vessels present in Gal-9 M- or PBS-injected
plug cryosections using von Willebrand factor (vWF)
obtained from Dako (Carpinteria, CA, USA) [10–13,
15]. To determine the role of signaling molecules in
Gal-9 M-mediated angiogenesis in vivo, the mouse
Matrigel plug assay was performed with Gal-9 M in
the presence or absence of the signaling inhibitors
SB203580 (p38 MAPK inhibitor) and SP600125 (Jnk
inhibitor). All experiments performed with animals
were done with the approval of the University of
Michigan’s University Committee on Use and Care of
Animals. The University of Michigan is accredited by
the Association for Assessment and Accreditation of La-
boratory Animal Care International, and the animal care
and use program conforms to the National Institutes of
Health standards set forth in the Guide for the Care and
Use of Laboratory Animals (revised 2011).
MN chemotaxis assays
MNs were isolated from normal human blood, and
chemotaxis assays were performed with MNs using
48-well modified Boyden chambers (Neuro Probe, Cabin
John, MD, USA) as described elsewhere [17–20]. Gal-9
M was used at two different concentrations. PBS and
N-formylmethionyl-leucyl-phenylalanine (fMLP) served
as negative and positive controls, respectively. Each test
group was assayed in quadruplicate. Three high-power
fields (HPFs) at ×400 magnification were counted in
each replicate well by a blinded observer. Written
informed consent was obtained from all subjects, and
the study was approved by the University of Michigan
Institutional Review Board.
Acute inflammatory arthritis induced by injecting Gal-9
into mouse knees
Female C57BL/6 mice (aged 6–8 weeks) were anes-
thetized using ketamine (80 mg/kg body weight) on
day 0, and knee circumferences were measured. Mice
were given intra-articular knee injections of either
PBS (20 μl) or Gal-9 M at 139.5 nmol/L or 1.39
μmol/L [18, 20, 21]. After 24 h, mouse knees were
measured by an observer blinded to the experimental
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groups. Mice were then euthanized, and their knees were
harvested, stored in optimum cutting temperature medium,
and cryosectioned. Immunofluorescence was performed
with F4/80 antibody (GeneTex, Irvine, CA, USA) to detect
MNs/macrophages and Alexa Fluor 555 goat antirat im-
munoglobulin G (Thermo Fisher Scientific) was used as a
secondary antibody [11, 17, 18].
Statistical analysis
For statistical analysis, nonparametric Mann-Whitney
U tests were used to determine statistical significance
between various groups for most assays. Where
appropriate, Student’s t test was used to evaluate
significance between groups. Results are expressed as
the mean ± SEM. p Values less than 0.05 were con-
sidered significant.
Results
Gal-9 M induces HMVEC migration in vitro
To determine the role of Gal-9 M in HMVEC chemo-
taxis, we performed HMVEC migration assays in modi-
fied Boyden chambers. We found that Gal-9 M induced
HMVEC migration at 2.79 nmol/L, 27.9 nmol/L, and
55.8 nmol/L at levels comparable to the positive control
bFGF (p < 0.0001). This increase was > 2-fold greater
than the negative control PBS (Fig. 1a).
Gal-9 M induces HMVEC chemotaxis via Erk1/2, Jnk, p38,
and PI3K
To assess the signaling pathways necessary for Gal-9 M-
stimulated cell migration, HMVEC chemotaxis was per-
formed in the presence or absence of signaling inhibitors.
The inhibitors of Erk1/2 (PD98059), Jnk (SP600125), and
p38 (SB203580) all significantly inhibited Gal-9 M-mediated
Fig. 1 Galectin-9 medium (Gal-9 M) induces human dermal microvascular endothelial cell (HMVEC) migration in vitro. a Gal-9 M induced HMVEC
migration at concentrations between 2.79 nmol/L and 55.8 nmol/L (p < 0.0001). n Number of the replicates in each group. b HMVEC chemotaxis
with various signaling inhibitors. Signaling inhibitors of Janus kinase (Jnk), extracellular signal-regulating kinases 1/2 (Erk1/2), and p38 significantly
reduced Gal-9 M-stimulated HMVEC chemotaxis compared with the control group (p < 0.05). n Number of experiments. c A chemotaxis assay
was performed with HMVECs transfected with Erk1/2 and p38 small interfering RNA (siRNA) for 48 h. HMVECs transfected with Erk1/2 and p38
siRNAs had significantly less migration in response to Gal-9 M (p < 0.05). n Number of replicates in each group. bFGF Basic fibroblast growth
factor, DMSO Dimethyl sulfoxide, HPF High-power field, PI3K Phosphatidylinositol 3-kinase
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HMVEC migration (p < 0.05), whereas an inhibitor of PI3K
(LY294002) did not (Fig. 1b). To confirm our data, we per-
formed HMVEC chemotaxis with cells transfected with
Erk1/2 and p38 siRNA using Gal-9 M as a stimulus. Gal-9
M-mediated HMVEC migration was decreased in cells
transfected with Erk1/2 and p38 siRNAs compared with
sham (scrambled)-transfected HMVECs (Fig. 1c). Sham
(scrambled)-transfected HMVECs were used as positive and
negative controls.
Gal-9 M induces HMVEC tube formation in vitro
HMVEC tube formation is a critical indicator of the an-
giogenic response and reflects capillary morphogenesis.
We measured the number of cordlike structures formed
after overnight incubation with various concentrations
of Gal-9 M from 3.49 nmol/L up to 111.6 nmol/L. We
found that Gal-9 M-induced HMVEC migration was sig-
nificantly higher between 13.95 and 55.8 nmol/L com-
pared with PBS (control) (p < 0.05), suggesting a role of
Gal-9 M in angiogenesis (Fig. 2a, b). The highest (111.6
nmol/L) and lowest (3.49 and 6.98 nmol/L) concentra-
tions of Gal-9 M did not induce significantly more tube
formation, suggesting a precisely regulated effect of Gal-
9 on HMVEC tube formation.
Gal-9 M induces HMVEC tube formation via Erk1/2, p38,
and Jnk signaling pathways
HMVEC tube formation assays were performed in the
presence or absence of signaling kinase inhibitors. The
inhibitors of Erk1/2, Jnk, and p38, but not PI3K, inhib-
ited Gal-9 M-mediated tube formation (p < 0.05) (Fig. 2c
and d). All inhibitors were used at 10 μmol/L concentra-
tions. HMVECs transfected with Erk1/2 and p38 siRNAs
formed significantly fewer tubes with Gal-9 M, confirm-
ing the role of Erk1/2 and p38 in Gal-9 M-mediated
signaling and endothelial cell (EC) tube formation
(Fig. 2e and f).
Gal-9 M activates phosphorylation of HMVEC Erk1/2, p38,
and Jnk
Western blotting experiments were performed to deter-
mine the effects of Gal-9 M-induced signaling molecules
in HMVECs. We found a time-dependent increase in
phosphorylation of Erk1/2, p38, and Jnk kinases in
HMVECs stimulated with Gal-9 M. HMVECs were
treated with signaling inhibitors for 1 h and stimulated
with Gal-9 M for 15 minutes. Western blotting was per-
formed to determine the cross-talk between signaling
molecules phosphorylated by Gal-9 M. Jnk phosphoryl-
ation was unaffected by inhibitors of p38 or Erk1/2
MAPK, indicating that these molecules were not up-
stream of Jnk. The phosphorylation of Erk1/2 was de-
creased by the Jnk inhibitor but not by inhibitors of p38
MAPK, demonstrating that Erk1/2 is downstream of
Jnk. These results suggest that Jnk is upstream of Erk1/2
in Gal-9-induced phosphorylation (Fig. 2g).
Gal-9 M stimulates angiogenesis in vivo
After finding that Gal-9 M induces HMVEC migration
and tube formation in vitro, we examined whether Gal-9
M induces angiogenesis in vivo by performing Matrigel
plug assays. Hemoglobin levels, an indirect measure of
angiogenesis, were ~ 2-fold higher in plugs containing
Gal-9 M compared with PBS control (p < 0.01) (Fig. 3a).
Some of the plugs were cryosectioned and stained for
vWF using rabbit antimouse vWF antibody (Dako). We
found a significant increase in blood vessels in the
Matrigel plugs injected with Gal-9 M compared with
PBS-injected plugs (p < 0.001) (Fig. 3b and c).
Jnk signaling pathway contributes to Gal-9 M-mediated
angiogenesis in vivo
To determine the effect of signaling inhibitors in Gal-9
M-mediated angiogenesis in vivo, Matrigel plug assays
were performed using chemical signaling inhibitors at a
10 μmol/L concentration. Gal-9 M-induced angiogenesis
was significantly reduced in Matrigel plugs containing
an inhibitor of Jnk (SP600125) (p < 0.02), whereas the
signaling inhibitor of p38 had no effect (Fig. 3d). We
found a significant decrease in Gal-9 M-mediated
HMVEC migration and tube formation in the presence
of p38 inhibitor in vitro; yet, the p38 inhibitor was un-
able to inhibit Gal-9 M-induced angiogenesis in vivo.
This suggests that the concentration of the inhibitor
might not be maintained locally in vivo and/or that
other signals available exclusively in vivo might be able
to overcome the effect of the inhibitor.
Gal-9 M induces MN chemotaxis in vitro
We used two concentrations of Gal-9 M (27.9 nmol/L
and 139.5 nmol/L) to examine its role in MN migration.
At both concentrations, Gal-9 M-induced MN migration
was significantly higher than with PBS control (p <
0.05), suggesting that Gal-9 M is a potent human MN
chemoattractant (Fig. 3e). We did not find a significant
difference in MN migration in response to two different
concentrations of Gal-9 M.
Gal-9 M causes acute inflammation in mouse knees
Gal-9 M was injected into mouse knees to determine
whether Gal-9 M had proinflammatory effects when
injected directly into mouse knees. Knees injected with
139.5 nmol/L of Gal-9 M exhibited a 3-fold increase in
knee circumference (p < 0.0068) compared with PBS.
Comparatively, knees injected with 1.39 μmol/L showed
an ~ 2-fold increase in knee circumference (p < 0.01)
(Fig. 3f). F4/80-positive MNs/macrophages were markedly
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elevated in Gal-9 M-injected knees compared with those
injected with PBS (Fig. 3g).
Discussion
Gal-9 is currently known as a versatile immunomodula-
tor that affects a host of cell types, including vascular
ECs and leukocytes. The complex and even conflicting
functions of Gal-9 can be attributed to the location of its
binding to glycosylated proteins, disparate properties of
its isoforms, the unique N- and C-CRD structure, and
different receptors, such as T-cell immunoglobulin
mucin 3 (TIM-3) on immunocytes [1]. Gal-9 also binds
to protein disulfide isomerase on T cells and thereby
influences T-cell migration by increasing the reduction
of disulfide bonds on integrins [22].
The exact contribution of Gal-9 in EC biology and
angiogenesis remains elusive. Discrepancies regarding
the role of Gal-9 in angiogenesis may be based on the
existence of alternative splice variants, the concentra-
tions of Gal-9 employed in various assays, and the types
of ECs used [3]. Heusschen et al. found that Gal-9 M
enhanced sprout formation and migration of primary
ECs, two aspects of angiogenesis, using human umbilical
vein endothelial cells. However, the same research group
observed a contradictory effect of Gal-9 M on human
microvascular endothelial cell-1 (HMEC-1), a human EC
line, whereby Gal-9 M decreased proliferation and
Fig. 2 Galectin-9 medium (Gal-9 M) induces human dermal
microvascular endothelial cell (HMVEC) tube formation in vitro. a
Gal-9 M induced HMVEC tube formation on growth factor-reduced
(GFR) Matrigel that was higher than that induced with PBS (p <
0.05). b Photomicrographs at ×20 magnification of tube formation
assay with PBS, a negative control, and basic fibroblast growth factor,
a positive control, and Gal-9 at various concentrations. We did not
find a significant increase in HMVEC tube formation in response to
Gal-9 M at 111.6, 6.97, and 3.49 nmol/L concentrations. Arrows indicate
tubes formed in response to each group. c Matrigel tube formation
assay with Gal-9 using various signaling inhibitors. Inhibitors of p38,
Janus kinase (Jnk), and extracellular signal-regulating kinases 1/2 (Erk1/
2) significantly reduced Gal-9 M-induced tube formation (p < 0.05),
whereas the signaling inhibitor of phosphatidylinositol 3-kinase did
not. d Photographs at ×20 magnification of tube formation assay with
various signaling inhibitors. Arrows indicate HMVEC tubes formed in
response to Gal-9 M with or without signaling inhibitors. e and f siRNA
directed against Erk1/2 and p38 significantly reduced HMVEC tube
formation on Matrigel in response to Gal-9 M compared with sham
(scrambled)-transfected HMVECs. g Western blots with HMVECs
stimulated with Gal-9 M. HMVECs were stimulated for 5, 15, 30, and 45
minutes with Gal-9 M (27.9 nmol/L). Shown are one of two
representative blots for incremental increases in phosphorylation for
Erk1/2, p38, and Jnk proportional to length of time stimulated. Western
blots were performed with lysates of HMVECs stimulated with Gal-9 M
in the presence or absence of signaling inhibitors. Jnk signaling
inhibitor decreased Erk1/2 phosphorylation, suggesting that Jnk is
upstream of Erk1/2 in the Gal-9 M-induced signaling pathway.
Additionally, Jnk inhibitor did not reduce p38 phosphorylation and
vice versa
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Fig. 3 Galectin-9 medium (Gal-9 M) induces angiogenesis and acute inflammation in vivo. a Matrigel plug angiogenesis assay with PBS negative
control and Gal-9 M (139.5 nmol/L). Matrigel plugs containing Gal-9 M had significantly more hemoglobin than the PBS control group (p < 0.01).
n Number of mice per group. b and c Cryosection of Matrigel plugs stained for von Willebrand factor (vWF) displayed a significant increase in
blood vessel formation in response to Gal-9 M compared with PBS, a negative control (p < 0.001). d Matrigel plug assay with Janus kinase (Jnk)
and p38 signaling inhibitors. Jnk inhibitor significantly reduced Gal-9 M-stimulated angiogenesis in the Matrigel plugs, whereas p38 inhibitor did
not. n Number of mice per group (p < 0.02). e Gal-9 M induces in vitro monocyte (MN) chemotaxis. MN chemotaxis assays were performed using
a modified Boyden chamber. MN migration was determined in response to Gal-9 M. PBS and N-formylmethionyl-leucyl-phenylalanine (fMLP) were
used as negative and positive controls, respectively. Three high-power fields (HPFs) were counted per well, and the assay was performed in
quadruplicate. n Number of replicates. Means are presented with SEM, and p values < 0.05 were considered significant. f Acute inflammatory
arthritis in mouse knees injected with Gal-9 M. Results were measured as knee circumference from the day of injection (day 0). Gal-9 M at
concentrations of 139.5 nmol/L and 1.39 μmol/L in 20 μl of PBS induced significantly higher inflammation. At 139.5 nmol/L, knee circumference
was increased by ~ 3-fold (p < 0.0068), whereas at 1.39 μmol/L, the increase in knee circumference was 2-fold (p < 0.01). g F4/80 staining of
mouse knee cryosections injected with Gal-9 M and PBS. Knees were snap-frozen and cryosectioned, then stained with 4′,6-diamidino-2-phenylindole
(DAPI; blue) and F4/80 (red). Gal-9 M-injected knees had increased MN/macrophage staining compared with those injected with PBS
O’Brien et al. Arthritis Research & Therapy  (2018) 20:31 Page 6 of 8
migration of HMEC-1 cells [3]. Our data support the
notion that Gal-9 M contributes to migration and tube
formation in primary human ECs. Our data are also in
agreement with previous reports that higher concentra-
tions of Gal-9 might be involved in apoptosis of ECs,
because we found that Gal-9 triggered HMVEC apop-
tosis on GFR Matrigel at relatively high concentrations
(data not shown), whereas lower concentrations of
Gal-9 M induced HMVEC tube formation on GFR
Matrigel (Fig. 2).
Gal-9 M induced phosphorylation of Jnk, p38, and
Erk1/2 MAPK in HMVECs in a time-dependent manner.
In terms of Gal-9 M signaling in HMVECs, we found
cross-talk between Jnk and Erk1/2 MAPK, because an
inhibitor of Jnk decreased Jnk and Erk1/2 phosphoryl-
ation, suggesting that Jnk is upstream of Erk1/2.
Heusschen et al. found that Gal-9 M induced angio-
genesis in the chick chorioallantoic membrane assay [3].
Our data are in agreement with those of Heusschen et
al. because we found a significant increase in blood ves-
sel formation in response to Gal-9 M in the Matrigel
plug angiogenesis assay, another murine model of angio-
genesis. The role of signaling molecules such as Erk1/2,
Jnk, and p38 in angiogenesis is well known [11, 15].
Erk1/2, Jnk, and p38 mediate Gal-9 M-induced HMVEC
migration and Matrigel tube formation. After finding a
role for these signaling molecules in Gal-9 M-induced
angiogenesis in vitro, we tested their contribution to
Gal-9 M-induced angiogenesis in vivo. Jnk contributed
to Gal-9 M-induced angiogenesis in the Matrigel plug
assay. In contrast, p38 MAPK did not appear to be
required in Gal-9-induced angiogenesis in vivo.
The effects of galectins are complex and vary depend-
ing upon the route of administration, concentration,
intracellular or extracellular localization, and the type of
inflammatory model used. There are some controversies
regarding the functions of Gal-9 in inflammatory models
of arthritis. Anderson et al. found that Gal-9 and its
receptor TIM-3 contribute to inflammation by increas-
ing proinflammatory cytokines such as tumor necrosis
factor-α (TNF-α) expression from MNs and dendritic
cells, whereas Arikawa et al. found that Gal-9 suppresses
murine arthritis and TNF-α secretion [23, 24]. Gal-9 is a
chemoattractant for neutrophils and eosinophils, but
scant evidence exists to support a role for Gal-9 in acute
models of inflammation that involve MN recruitment
[25, 26]. Our data support the notion that Gal-9 contrib-
utes to leukocyte migration and induces MN migration
in vitro and in vivo, indicating involvement of Gal-9 in
acute inflammation [25, 26].
Some studies suggest that Gal-9 functions as a negative
regulator in immune complex-associated arthritis models
[7, 23, 27]. In these studies, the effect of Gal-9 M was
examined in chronic inflammatory arthritis development
by injecting Gal-9 systemically in models that are T-cell-
dependent. In contrast to researchers in the above-
described studies, Iqbal et al. did not find a decrease in
inflammation during the first 24 h when Gal-9 M was
injected systemically in the mouse carrageenan paw
edema model, an acute model of inflammation [28]. Our
data are in agreement with those of Iqbal et al. in indicat-
ing that Gal-9 M induces significantly higher inflamma-
tion and MN migration when injected directly into mouse
knees. Notably, intra-articular but not systemic injection
of Gal-9 M would be expected to generate a chemotactic
gradient from the circulation into the joint. This suggests
that the effect of Gal-9 M depends upon the route of
administration and the type of murine inflammatory
model used.
Conclusions
This study suggests that Gal-9 induces angiogenesis and
that Jnk, Erk1/2, and p38 play an important role in Gal-9
M-mediated angiogenesis. The involvement of Gal-9 M in
MN recruitment renders it a novel therapeutic target in
angiogenesis and acute inflammatory conditions.
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